Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to ENvue Medical, Inc. (NASDAQ: FEED) regulatory filings once they are available through the SEC’s EDGAR system. ENvue describes itself as a medical technology company focused on non-invasive and minimally invasive solutions, including the ENvue Navigation Platform for feeding-tube placement and acoustic-based therapeutic devices such as PainShield and UroShield.
For a company with these activities, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on technology platforms, risk factors related to medical devices, research and development efforts, and the regulatory environment for enteral care and acoustic-based therapies. Current reports on Form 8-K can describe material events such as product launches, strategic programs, or significant corporate changes.
When insider transaction reports on Form 4 are filed, they can show purchases or sales of ENvue equity by directors, officers, or other insiders, which some investors review alongside the company’s technology and commercialization updates. Proxy statements on Schedule 14A, when filed, may provide information on governance, board composition, and executive compensation in the context of ENvue’s medical technology focus.
On Stock Titan, ENvue Medical filings are paired with AI-powered summaries designed to explain the main points of lengthy documents, highlight key sections, and make complex regulatory language easier to understand. As new ENvue filings are released on EDGAR, this page updates so users can quickly review the latest 10-K, 10-Q, 8-K, and Form 4 disclosures along with plain-language AI insights.
Bank of America Corp, Bank of America NA, and BofA Securities, Inc. jointly reported their initial beneficial ownership in Envue Medical, Inc. as 10% owners. The filing shows indirect ownership of 234,056 shares of common stock, held through Bank of America’s subsidiaries.
The 10% ownership status is based on 1,088,192 outstanding shares disclosed in Envue Medical’s Form 424B3 prospectus, which reports totals as of December 5, 2025. That prospectus covers the potential resale of up to 7,962,279 shares of common stock and notes that issuing additional shares could materially increase shares outstanding and substantially dilute existing stockholders.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.
ENvue Medical, Inc. director Zeev Jhoshua Rotstein filed an initial insider ownership report on Form 3. The filing identifies him as a director of the company and indicates that he does not beneficially own any non-derivative or derivative securities of ENvue Medical. Both ownership tables are blank, and the explanation of responses clearly states that no securities are beneficially owned.